Empliciti

Empliciti (elotuzumab) is a monoclonal antibody targeting SLAMF7, approved to treat multiple myeloma.

Type of Molecule

Biologic

Target

SLAMF7

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Multiple Myeloma (MM) First Line US, EU
Phase 3
Multiple Myeloma (MM) Second Line US, EU
Approved